Bioelectronic medicine, or electroceuticals, is the use of electrical stimulation to treat diseases of the human body in ways that current pharmaceutical interventions cannot. Though the term "bioelectronic medicine" is relatively new, electrical stimulation has been used for the treatment of diseases since the invention of the artificial pacemaker in the early 1900s.

 

From the development of the implantable artificial pacemaker, the field of bioelectronic medicine has expanded into the treatment of many other diseases. This report focuses on emerging areas of electrical neuromodulation, or the application of electrical stimulation to specific nerves within human body. Electrical neuromodulation has been used to treat illnesses such as chronic pain and Parkinson's disease, and can be used to restore function to muscles, as well as the senses of hearing and sight.

 

Electrical neuromodulation began in the 1960s with the development of stimulators for the central nervous system. The spinal cord and areas of the brain were targeted for the treatment of chronic pain and movement disorders respectively. Both fields have remained relatively unchanged in the last 30 years, and thus this report explores the emerging technologies that are disrupting this industry.

 

More recently, there has been increasing interest in developing bioelectronic medicine that modulates the peripheral nervous system. In this area, companies are particularly interested in electrical neuromodulation of the vagus nerve. Leading this effort are SetPoint Medical and Galvani Bioelectronics, two high profile companies which have been backed by industry giants in the medical device, technology, and pharmaceutical industries. Modulation of the vagus nerve promises to treat a myriad of diseases, including diabetes and rheumatoid arthritis.

 

Bioelectronic medicines have enormous opportunities in the treatment of chronic diseases and disorders, especially if they can replace traditional pharmaceutical medicines. Innovators in the field are driving down the size of components and improving electrode technologies to provide greater patient comfort and less invasive implantation procedures. Others are exploring non-invasive devices that can provide electrical neuromodulation through the skin.

 

This report provides an overview of devices for cardiac rhythm management, cochlear implants, and retinal implants, and gives a comprehensive analysis of companies developing electrical neuromodulators of both the central and peripheral nervous systems. Included in this report are devices that stimulate the spinal cord (including dorsal root ganglion), brain, vagus nerve, sacral nerve, tibial nerve, trigeminal nerve, and many others.

 

In this report, the market for bioelectronic medicine is forecast to exceed $60 billion by the year 2029. The 10-year market forecast is broken down into individual markets of cardiac, cochlear, retinal, central nervous system and peripheral nervous system implants.

所有报告购买订单均包括与一名专家分析师进行 30 分钟的电话交谈，专家分析师将帮助您将报告中的重要发现与您正在处理的业务问题联系起来。这需要在购买报告后的三个月内使用。

如果您对这一报告有任何疑问，请随时联系我们的报告团队 research@IDTechEx.com 或致电我们的销售经理：

AMERICAS (USA): +1 617 577 7890

ASIA (Japan): +81 3 3216 7209

ASIA (Korea): +82 10 3896 6219

ASIA: +81 70 3152 1209

EUROPE (UK) +44 1223 812300